Which Kind Of Cyclopamine I Truly Truly Want

7; median 69.5). Patient age distribution was: 0.297). Multivariate analysis confirmed that gender (P http://www.selleckchem.com/products/Cyclopamine.html cancer studies have inconsistently shown an association of age and gender with fatigue, results from Connect? CLL indicate that baseline fatigue at initiation of CLL treatment is worse and has greater impact among women than men when age and line of therapy are considered. Future analyses should determine how fatigue may change relative to treatment and response. 467 TREATMENT OF ELDERLY PATIENTS WITH CLL: DOES BENDAMUSTINE REPLACE CHLORAMBUCIL AS "" STANDARD OF CARE"" ? W. Knauf,1 W. Abenhardt,2 A. Nusch,3 R. Grugel,4 N. Marschner.5 1Onkologische Gemeinschaftspraxis, Frankfurt a. M., Germany, 2MOP Elisenhof, Muenchen, Germany, 3 Praxis fuer Haematologie und Internistische Onkologie, Velbert, Germany, 4iOMEDICO, Freiburg i. Br., Germany, 5Praxis fuer Interdisziplinaere Onkologie & Haematologie, Freiburg i. Br., http://www.selleckchem.com/products/BI-2536.html Germany Introduction: Recently, bendamustine and rituximab have been approved for treatment of patients (pts) with chronic lymphocytic leukaemia (CLL). Clinical registries with their insight into real-life treatment can show whether new therapeutic options change daily practice. Methods: The "" Tumour Registry Lymphatic Neoplasms"" prospectively collects data on the therapy of pts with various types of lymphoid B-cell neoplasms treated by office-based haematologists in Germany. A broad set of data regarding pts and tumour characteristics, co-morbidities, systemic treatments, response rates, http://www.selleck.cn/products/gsk126.html progression-free and overall survival are recorded. Pts are followed for 5 years. Since May 2009, 114 sites have recruited a total of 3080 pts. Results: 493 pts with CLL received systemic 1st-line therapy (65% male, median age at start of therapy 71 years (yrs)). Rituximab is part of 84% of 1st-line therapies. Bendamustine is part of 61% of 1st-line therapies, mostly in combination with rituximab (BR, 54%). Fludarabine is part of 30% of 1st-line therapies, mostly in combination with cyclophosphamide rituximab (FCR, 24%). Chlorambucil (Clb) is part of 7% of 1st-line therapies. Pts receiving BR, FCR or Clb differ. BR and Clb are applied preferably in elderly pts (median age: FCR 65.4 vs. BR 71.2 vs. Clb 82.7 yrs). From 2009 to 2012 the use of BR increased from 41% to 63% of 1st-line therapies, while the use of FCR decreased from 33% to 20%. To date 12% of pts have received subsequent therapy.